Biomarkers Technologies & Commercial Wight Reviewed by Visiongain

25 Sep 2012 • by Natalie Aster

Future research in cardiovascular disease biomarkers is likely to centre on improved use of troponin, as well as the development of other, novel markers. These include DNA methylation biomarkers and miRNA. In animal models, it has been found that histone modifications - an epigenetic modification - are linked to the developed of atherosclerosis and cardiovascular disease. The levels of certain miRNA circulating in the blood have also been found to increase following acute myocardial infarction. However, only small-scale human studies and animal models have been used to assess the potential of miRNA in cardiovascular disease. Expanded studies testing these biomarkers will be one future direction for research in this sector.

The new Visiongain's study “Biomarkers: Technological and Commercial Outlook 2012-2022” analyses the commercial potential for biomarker products and services.

Report Details:

Biomarkers: Technological and Commercial Outlook 2012-2022
Published: July, 2012
Pages: 162
Price: US$ 2.642,00

There are discussions of many issues and developments in the study:

  • Intellectual property for biomarkers 
  • Regulatory guidance for biomarker validation and qualification 
  • Improvements to discovery instruments and tools 
  • Outsourcing biomarker discovery and development 
  • Collaboration between public institutions and the pharmaceutical industry 
  • Challenges in co-developing drugs and diagnostics.

More information can be found in the report “Biomarkers: Technological and Commercial Outlook 2012-2022” by Visiongain.

To order the report or ask for sample pages contact


MarketPublishers, Ltd.
Tanya Rezler
Tel: +44 208 144 6009
Fax: +44 207 900 3970